Scientists can predict how long prostate cancer patients will respond to olaparib

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug olaparib, according to new research published in the journal Cancer Cell.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup